Table 1 Demographic and clinical characteristics of HD patients with COVID-19
From: Prolonged RT-PCR test positivity in hemodialysis patients with COVID-19
Variables | All patients | Unvaccinated patients | Vaccinated patients | p Value |
|---|---|---|---|---|
(n. 151) | (n. 42) | (n. 109) | ||
Age, yr | 70.1 (54.3–81.6) | 72.2 (54.8–84.1) | 68.4 (54–80.2) | 0.27 |
(range) | (20.5–94.3) | (31.7–87.5) | (20.5–94.3) |  |
Male, n. (%) | 90 (59.6) | 27 (64.3) | 63 (57.8) | 0.57 |
Origin, n. (%) | Â | Â | Â | 0.012 |
Caucasian | 95 (63.6) | 32 (76.2) | 64 (58.7) | Â |
African | 50 (33.1) | 7 (16.7) | 43 (39.4) | Â |
Other | 5 (3.3) | 3 (7.1) | 2 (1.8) | Â |
Dialysis vintage, yr | 4.2 (1.5–8.5) | 3.9 (1.2–8.8) | 4.3(2.5–7.5) | 0.73 |
Kt/V | 1.2 (1–1.3) | 1.1 (1–1.3) | 1.2 (1-.4) | 0.61 |
Hemoglobin, gr/dl | 11.3 (10.4–12.1) | 11.3 (10.5–12.4) | 11.3 (10.2–12.1) | 0.46 |
Albumin, gr/dl | 3.5 (3.3–3.9) | 3.5 (3.2–4) | 3.5 (3.3–3.9) | 0.6 |
Phosphorus mg/dL | 5 (4.1–6.3) | 5.1 (4.4–6) | 4.9 (4–6.3) | 0.35 |
Diabetes, n. (%) | 40 (26.5) | 14 (33.3) | 26 (23.9) | 0.30 |
Immunosuppressed pts, n. (%) | 20 (13.4) | 5 (12.2) | 15 (13.9) | 0.99 |
Cancer pts, n. (%) | 5 (3.3) | 1 (2.4) | 4 (3.7) | 0.99 |
COVID-19 | ||||
IgG Ab (BAU/mL) | 7580 (172–17,200) | – | 7580 (172–17,200) |  |
RT-PCR positivity, days* | 30 (21–40) | 42 (31–56) | 27.5 (19.7–35.2) |  < 0.001 |
Ct value, days* | 18.5 (13.7–26.5) | 16.3 (8.1–31.7) | 18.5 (13.2–27.5) | 0.88 |
Severe COVID-19, n. (%) | 35 (23.2) | 19 (45.2) | 16 (14.8) |  < 0.001 |
Death, n. (%) | 22 (14.5) | 17(40.5) | 5 (4.6) |  < 0.001 |